[go: up one dir, main page]

NO20072136L - Substance that promotes GH secretion and its use - Google Patents

Substance that promotes GH secretion and its use

Info

Publication number
NO20072136L
NO20072136L NO20072136A NO20072136A NO20072136L NO 20072136 L NO20072136 L NO 20072136L NO 20072136 A NO20072136 A NO 20072136A NO 20072136 A NO20072136 A NO 20072136A NO 20072136 L NO20072136 L NO 20072136L
Authority
NO
Norway
Prior art keywords
individual
improve
secretion
improving
promotes
Prior art date
Application number
NO20072136A
Other languages
Norwegian (no)
Inventor
Thierry Abribat
Villers Andre De
Soraya Allas
Denis Gravel
Alcide Chapdelaine
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/969,463 external-priority patent/US7316997B2/en
Priority claimed from CA2485472A external-priority patent/CA2485472C/en
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of NO20072136L publication Critical patent/NO20072136L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)

Abstract

Oppfinnelsen angår anvendelsen av en GH-sekresjonsfremmer (for eksempel GRF eller en analog derav) for (1) å endre et lipid parameter i et individ; (2) å endre en kroppssammensetningsparameter i et individ; (3) å behandle en tilstand karakterisert ved manglende eller nedsatt bendannelse i et individ; (4) å forbedre dagtids årvåkenhet og/eller kognitiv funksjon i et individ; (5) å forbedre en metabolsk tilstand i et individ; (6) å forbedre anabolisme i en katabolsk tilstand i et individ, og/eller (7) å forbedre og/eller rekondisjonere immun funksjon i et individ.This invention relates to the use of a GH secretion promoter (e.g., GRF or an analog thereof) to (1) alter a lipid parameter in an individual; (2) changing a body composition parameter in an individual; (3) treating a condition characterized by missing or impaired bone formation in an individual; (4) improving daytime alertness and / or cognitive function in an individual; (5) improving a metabolic state in an individual; (6) to improve anabolism in a catabolic state in an individual, and / or (7) to improve and / or recondition immune function in an individual.

NO20072136A 2004-10-20 2007-04-24 Substance that promotes GH secretion and its use NO20072136L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/969,463 US7316997B2 (en) 2003-05-29 2004-10-20 GH secretagogues and uses thereof
CA2485472A CA2485472C (en) 2004-10-20 2004-10-20 Gh secretagogues and uses thereof
PCT/CA2005/001611 WO2006042408A1 (en) 2004-10-20 2005-10-20 Gh secretagogues and uses thereof

Publications (1)

Publication Number Publication Date
NO20072136L true NO20072136L (en) 2007-07-16

Family

ID=36202645

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072136A NO20072136L (en) 2004-10-20 2007-04-24 Substance that promotes GH secretion and its use

Country Status (6)

Country Link
EP (1) EP1812048A4 (en)
JP (1) JP2008516994A (en)
KR (1) KR101228229B1 (en)
AU (1) AU2005297366B2 (en)
NO (1) NO20072136L (en)
WO (1) WO2006042408A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101623985B1 (en) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Stitched polypeptides
CN101678083A (en) * 2007-04-04 2010-03-24 瑟瑞技术公司 pharmaceutical formulations of ghrh molecules
DK2603600T3 (en) 2010-08-13 2019-03-04 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
KR20140027284A (en) 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 Growth hormone releasing factor (grf) analogs and uses thereof
BR112014009418A2 (en) 2011-10-18 2017-04-18 Aileron Therapeutics Inc peptidomimetic macrocycles
CN112500466B (en) 2012-02-15 2022-05-03 艾瑞朗医疗公司 Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
CA2961258A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458764B1 (en) * 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US6518292B1 (en) * 1999-03-12 2003-02-11 Bristol-Myers Squibb Co. Heterocyclic aromatic compounds usefuls as growth hormone secretagogues
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
EP1675610A4 (en) * 2003-10-20 2010-04-28 Theratechnologies Inc USE OF SOMATOSTATIN ANALOGS IN THE TREATMENT OF PATIENTS SUFFERING FROM CACHEXIA

Also Published As

Publication number Publication date
KR101228229B1 (en) 2013-01-31
WO2006042408A1 (en) 2006-04-27
KR20070069207A (en) 2007-07-02
EP1812048A1 (en) 2007-08-01
AU2005297366A2 (en) 2006-04-27
WO2006042408A9 (en) 2007-05-24
AU2005297366A1 (en) 2006-04-27
EP1812048A4 (en) 2012-01-18
JP2008516994A (en) 2008-05-22
AU2005297366B2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
NO20072136L (en) Substance that promotes GH secretion and its use
EA201000399A1 (en) COMPOSITIONS AND METHODS OF USING PRO-ISLAND PEPTIDES AND THEIR ANALOGUES
ATE463247T1 (en) BUPROPION METABOLITES FOR THE TREATMENT OF ANXIETY
MX338122B (en) Therapeutic epitopes and uses thereof.
YU37304A (en) Specific binding agents of human angiopoietin-2
MXPA03010843A (en) Use of azetidinone substituted derivatives in the treatment of alzheimer's disease.
WO2004019884A3 (en) Agents and methods for enhancing bone formation
EA200600055A1 (en) AGONISTS OF MELANOCORTIN 4 (MK4) RECEPTOR AND THEIR APPLICATION
MXPA05007182A (en) Complexes of protein crystals and ionic polymers.
HK1044545A1 (en) Human beta-secretase enzyme, inhibitors and their compositions and uses
EP2213684A3 (en) Nogo-a antibodies for the treatment of Alzheimer disease
GB0108592D0 (en) Therapeutic agents
ATE470676T1 (en) ANTI-VEGF-2 ANTIBODIES
DE60110054D1 (en) Cardioprotektive phosphonate
MX2010000380A (en) Glp-1-fc fusion protein formulation.
MA29222B1 (en) COSMETIC COMPOSITION WITH APPROPRIATE SKIN APPLICATION FOR RELAXING EXPRESSION WRINKLES
EA200500782A1 (en) TREATMENT OF HEMORRHAGIC SHOCK
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
TW200735868A (en) Compositions and methods for treating CNS disorders
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
ATE360076T1 (en) ALKALINE CERAMIDASE (E.C. 3.5.1.23) GENE CODING FROM PSEUDOMONAS AERUGINOSA
DE602005020178D1 (en) 5,6,7-TRIHYDROXYPHEPTANIC ACIDS AND ANALOGS FOR THE TREATMENT OF EYE DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVES AND ANGIOGENIC REACTIONS
DE60228988D1 (en) MONOHYROXYCARBAMEZEPINE FOR USE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF AFFECTIVE PSYCHOSIS, ATTRACTIVE DISORDERS AND NEUROPATHIC PAIN
WO2003094851A3 (en) 1,1- and 1,2-bisphosphonates as apoliprotein e modulators

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application